• Skip to main content
  • Skip to footer
3Rs Collaborative-lead project with FDA
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Products
    • PhysioMimix® Core Microphysiological System
    • Consumables
      • PhysioMimix® Multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Technology
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix Core

cnb1476_physiomimix-core_mark_mocks_system_v2
Learn more

Consumables

Multi-chip plates
3D validated cells
NASH-in-a-box
Bioavailability assay kit: Human 18
DILI assay kit: Human 24
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Discover the applications


Investigate the validated core application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

PhysioMimix® Bioavailability assay kit: Human 18 for simultaneous oral and intravenous in vitro bioavailability profiling

April 10, 2025

Resource > Videos and animations >

PhysioMimix® Bioavailability assay kit: Human 18 for simultaneous oral and intravenous in vitro bioavailability profiling

Filed under: ADME and Drug bioavailability

cnb1385 bio assay vid v1 | in vitro bioavailability

Video content if present

The PhysioMimix® Bioavailability Assay Kit: Human 18, the only in vitro bioavailability tool available for profiling human drug bioavailability, is set to transform how CROs, pharmaceutical, and biotech companies approach preclinical ADME testing.

The all-in-one kit facilitates effortless Organ-on-a-Chip adoption into existing workflows, bridging the knowledge gap between in vitro and in vivo studies, to enhance lead optimization and preclinical testing pipelines ahead of in vivo animal and first-in-human trials.

Why Bioavailability Matters

Understanding a drug’s bioavailability is crucial for determining its therapeutic efficacy and safety. Accurate bioavailability assessments inform optimal dosing regimens and are essential for regulatory approvals prior to clinical trials. Traditional methods, including isolated in vitro assays and animal studies, often fall short in predicting human responses due to assay limitations and physiological differences.

The PhysioMimix® Advantage

Our Bioavailability assay kit: Human 18 leverages the PhysioMimix Gut/Liver-on-a-chip model to offer a unique solution that combines the abilities of the:

  • RepliGut®– Planar Jejunum model: Developed by Altis Biosystems, this model accurately mimics the human intestinal barrier, providing a more physiologically relevant alternative to traditional Caco-2 assays.
  • PhysioMimix® Liver-on-a-chip: Our FDA-recognized liver model maintains high metabolic activity, closely replicating human liver functions for more accurate drug metabolism studies.

By fluidically linking these two models, the kit allows for simultaneous simulation of oral and intravenous drug dosing within a single experiment. This interconnected system enables assessment of intestinal absorption, intestinal metabolism, and hepatic clearance concurrently, offering a more comprehensive understanding of a drug’s bioavailability in humans.

To learn more, visit the Bioavailability assay kit: Human 18 product page

Note that from October 2025, the PhysioMimix® Multi-organ System mentioned in the video has been replaced by the universal PhysioMimix Core microphysiological system.

Video content if present

Speak to our experts

Request a meeting with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Regulatory | Accessibility
Website terms | Terms of sale

Product Recycling

©2025 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • UK plans to phase out animal testing faster in favor of alternative methods November 11, 2025
  • CN Bio launches all-in-one Organ-on-a-chip system, PhysioMimix® Core October 14, 2025
  • Regulatory Shifts and Validation: Key Insights from The World Congress on Alternatives and Animal Use in the Life Sciences Conference (WC13) September 30, 2025
Cyber Essentials Logo